IVF vs TCMD

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 11, 2026

IVF

32.2
AI Score
VS
IVF Wins

TCMD

24.6
AI Score

Investment Advisor Scores

IVF

32score
Recommendation
SELL

TCMD

25score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric IVF TCMD Winner
Revenue 1.64M 252.82M TCMD
Net Income -17.40M 13.18M TCMD
Net Margin -1063.0% 5.2% TCMD
Operating Income -1.20M 14.88M TCMD
ROE 64.0% 5.8% IVF
ROA -54.8% 4.5% TCMD
Total Assets 31.74M 291.29M TCMD
Cash 840,407 75.11M TCMD
Current Ratio 0.08 3.51 TCMD
Free Cash Flow -3.56M 12.24M TCMD

Relative Price Performance (Last 90 Days)

IVF 1M: +320.4% · 3M: +177.3% TCMD 1M: +21.6% · 3M: +14.4%

Current Technical Phase

IVF

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (8.3% over 20 days), RSI 88

RSI (14): 87.9 · Price: $2.69

TCMD

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 68

RSI (14): 67.5 · Price: $27.13

Fundamentals Snapshot

Metric IVF TCMD
Market Cap — —
Forward P/E -0.1 18.5
Trailing P/E 0.0 25.8
Revenue (TTM) — —
Revenue Growth 0.2% 0.1%
Gross Margin 0.4% 0.8%
Operating Margin -0.6% 0.1%
EPS 511.80 1.03
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, IVF is currently the stronger investment candidate, winning 1 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.